We are live on ! Find out more
XBIO icon

Xenetic Biosciences
XBIO

9 hedge funds and large institutions have $120K invested in Xenetic Biosciences in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.03% more ownership

Funds ownership: 0.38% → 2.41% (+2%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

49% less capital invested

Capital invested by funds: $235K → $120K (-$115K)

53% less funds holding

Funds holding: 19 → 9 (-10)

91% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 11

Holders
9
Holders Change
-10
Holders Change %
-52.63%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$59K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$19.7K
3
JEST
JTC Employer Solutions Trustee
Jersey
+$4

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$39.4K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$37.7K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$32.1K
4
HF
HRT Financial
New York
-$15K
5
State Street
State Street
Massachusetts
-$14.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$85K +$59K +15,831 +159%
Royal Bank of Canada
2
Royal Bank of Canada
Ontario, Canada
$17K +$19.7K +5,300 New
JEST
3
JTC Employer Solutions Trustee
Jersey
$9K +$4 +1 +0%
SPIA
4
Steward Partners Investment Advisory
New York
$6.23K – – –
TRCT
5
Tower Research Capital (TRC)
New York
$2.04K -$1.91K -514 -45%
Morgan Stanley
6
Morgan Stanley
New York
$967 – – –
NC
7
NewSquare Capital
Pennsylvania
$85 – – –
Wells Fargo
8
Wells Fargo
California
$36 – – –
Fidelity Investments
9
Fidelity Investments
Massachusetts
$22 -$56 -15 -68%
Vanguard Group
10
Vanguard Group
Pennsylvania
– -$39.4K -9,698 Closed
Geode Capital Management
11
Geode Capital Management
Massachusetts
– -$37.7K -9,155 Closed
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
– -$32.1K -7,782 Closed
HF
13
HRT Financial
New York
– -$15K -3,747 Closed
State Street
14
State Street
Massachusetts
– -$14.3K -3,467 Closed
TSS
15
Two Sigma Securities
New York
– -$8.21K -2,022 Closed
Northern Trust
16
Northern Trust
Illinois
– -$7.21K -1,776 Closed
Citadel Advisors
17
Citadel Advisors
Florida
– -$6.74K -1,637 Closed
E
18
Ergoteles
New York
– -$5.26K -1,277 Closed
GVAG
19
Great Valley Advisor Group
Delaware
– -$4.3K -1,060 Closed

XBIO Hedge Fund Activity: Q2 2023 in Review

9 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q2 2023, worth a combined $120K — down 49% from $235K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of XBIO and 1 opened new positions — a net loss of 10 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $59K. The largest seller was Vanguard Group, exiting entirely with an estimated $39.4K sold.

  • 9 institutional investors held Xenetic Biosciences (XBIO) as of Q2 2023, down from 19 in Q1 2023.
  • Funds reported $120K of Xenetic Biosciences stock for Q2 2023, down 49% quarter-over-quarter.
  • 1 fund opened new Xenetic Biosciences positions in Q2 2023 and 11 closed out, a net change of -10 holders.
  • The largest Xenetic Biosciences buyer in Q2 2023 was Renaissance Technologies, an estimated $59K added.
  • The largest Xenetic Biosciences seller in Q2 2023 was Vanguard Group, an estimated $39.4K sold.

Based on aggregated 13F filings for Q2 2023.